A Phase 3 interventional study of insulin degludec and insulin degludec in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 72 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-09.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 10th largest by enrollment, is one of 4 that started in 2009, is one of 49 in phase 3, and was the 4th registered.
10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Gan and Lee Pharmaceuticals, USA · Sites in Germany
Ages 18–70
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–70
Yanbing Li
Ages 18–70
Tonghua Dongbao Pharmaceutical Co.,Ltd
Ages 18–75
By country, each count listing its studies:
insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 50 · Phase 4 8
First in 2006; this study’s year is marked. 4 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 687 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 384 across the 70 interventional studies. Of the 64 that completed or were terminated, 51 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 70 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
645 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 27 open now, 31 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 645 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 61st largest by enrollment of the 430 interventional ones that give a count, is one of 30 that started in 2009, is one of 187 in phase 3, and was the 178th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing insulin degludec in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 645 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Africa, Asia, Europe and South America. The aim of this clinical trial is to compare NN1250 (insulin degludec (IDeg) with insulin glargine (IGlar) in patients with type 2 diabetes. Subjects treated with oral antidiabetic drug(s) (OAD(s)) should continue their current OAD treatment at the stable, prerandomisation dose level and dosing frequency.
10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
This study's enrollment of 687 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: insulin degludec
Drug: insulin degludec
Drug: insulin glargine
Injected s.c. (under the skin) once daily (alternative regimen). Dose was individually adjusted.
Injected s.c. (under the skin) once daily. Dose was individually adjusted.
Insulin glargine injected s.c. (under the skin) once daily. Dose was individually adjusted.
Change in Glycosylated Haemoglobin (HbA1c)
Change from baseline in HbA1c after 26 weeks of treatment
Time frame: Week 0, Week 26
Mean of 9-point Self Measured Plasma Glucose Profile (SMPG)
Mean of SMPG after 26 weeks of treatment. Plasma glucose measured: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, before bedtime, at 4 am and before breakfast.
Time frame: Week 26
Rate of Confirmed Hypoglycaemic Episodes
Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.
Time frame: Week 0 to Week 26 + 7 days follow up
Rate of Nocturnal Confirmed Hypoglycaemic Episodes
Rate of nocturnal confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L. Nocturnal hypoglycaemic episodes are defined as occurring between 00:01 and 05:59 a.m.
Time frame: Week 0 to Week 26 + 7 days follow up
The trial was conducted at 69 sites in 14 countries: Hungary (3 sites), Macedonia (1 site), Serbia (3 sites), Finland (7 sites), Norway (6 sites), United Kingdom (6 sites), Argentina (4 sites), Mexico (2 sites), South Africa (3 sites), India (10 sites), Malaysia (5 sites), Taiwan (3 sites), Russian Federation (8 sites) and Israel (8 sites).
| Milestone | IDeg OD FF | IDeg OD | IGlar OD |
|---|---|---|---|
| Started | 229 | 228 | 230 |
| Exposed | 230 | 226 | 229 |
| Completed | 203 | 204 | 203 |
| Not completed | 26 | 24 | 27 |
| Withdrew: Adverse event | 2 | 1 | 2 |
| Withdrew: Lack of efficacy | 2 | 2 | 1 |
| Withdrew: Protocol violation | 3 | 3 | 3 |
| Withdrew: Withdrawal criteria | 5 | 4 | 4 |
| Withdrew: Other | 14 | 14 | 17 |
Change from baseline in HbA1c after 26 weeks of treatment
| percentage of glycosylated haemoglobin | IDeg OD FF | IDeg OD | IGlar OD |
|---|---|---|---|
| Change in Glycosylated Haemoglobin (HbA1c) | -1.28 ± 1.00 | -1.07 ± 0.99 | -1.26 ± 1.07 |
Mean of SMPG after 26 weeks of treatment. Plasma glucose measured: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, before bedtime, at 4 am and before breakfast.
| mmol/L | IDeg OD FF | IDeg OD | IGlar OD |
|---|---|---|---|
| Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) | 7.9 ± 1.8 | 8.0 ± 2.1 | 7.8 ± 1.9 |
Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.
| Episodes/100 years of patient exposure | IDeg OD FF | IDeg OD | IGlar OD |
|---|---|---|---|
| Rate of Confirmed Hypoglycaemic Episodes | 364 | 363 | 348 |
Rate of nocturnal confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L. Nocturnal hypoglycaemic episodes are defined as occurring between 00:01 and 05:59 a.m.
| Episodes/100 years of patient exposure | IDeg OD FF | IDeg OD | IGlar OD |
|---|---|---|---|
| Rate of Nocturnal Confirmed Hypoglycaemic Episodes | 63 | 56 | 75 |
Collected over The adverse events were collected in a time frame of 26 weeks + 7 days follow up. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IDeg OD FF | — | 6/230 (2.6%) | 58/230 (25.2%) |
| IDeg OD | — | 8/226 (3.5%) | 57/226 (25.2%) |
| IGlar OD | — | 4/229 (1.7%) | 53/229 (23.1%) |
| Event | IDeg OD FF | IDeg OD | IGlar OD |
|---|---|---|---|
| Urinary tract infectionInfections and infestations | 2/230 | 0/226 | 0/229 |
| AnaemiaBlood and lymphatic system disorders | 0/230 | 1/226 | 0/229 |
| Myocardial infarctionCardiac disorders | 0/230 | 1/226 | 0/229 |
| AppendicitisInfections and infestations | 0/230 | 1/226 | 0/229 |
| Subcutaneous abscessInfections and infestations | 0/230 | 1/226 | 0/229 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/230 | 1/226 | 0/229 |
| Hypoglycaemic unconsciousnessMetabolism and nutrition disorders | 0/230 | 1/226 | 0/229 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/230 | 1/226 | 0/229 |
| Myelodysplastic syndromeNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/230 | 1/226 | 0/229 |
| Oral neoplasm benignNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/230 | 1/226 | 0/229 |
| Event | IDeg OD FF | IDeg OD | IGlar OD |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 23/230 | 20/226 | 18/229 |
| Upper respiratory tract infectionInfections and infestations | 20/230 | 11/226 | 20/229 |
| HeadacheNervous system disorders | 16/230 | 16/226 | 9/229 |
| DiarrhoeaGastrointestinal disorders | 10/230 | 14/226 | 10/229 |
| DizzinessNervous system disorders | 3/230 | 3/226 | 12/229 |
| Back painMusculoskeletal and connective tissue disorders | 12/230 | 9/226 | 6/229 |
| Age, Continuous(years) | IDeg OD FF | IDeg OD | IGlar OD | Total |
|---|---|---|---|---|
| Mean | 56.2 ± 10.3 | 56.5 ± 9.6 | 56.7 ± 8.8 | 56.4 ± 9.6 |
| Gender(Participants) | IDeg OD FF | IDeg OD | IGlar OD | Total |
|---|---|---|---|---|
| Female | 94 | 104 | 119 | 317 |
| Male | 135 | 124 | 111 | 370 |
| Glycosylated haemoglobin (HbA1c)(percentage of glycosylated haemoglobin) | IDeg OD FF | IDeg OD | IGlar OD | Total |
|---|---|---|---|---|
| Mean | 8.5 ± 1.0 | 8.4 ± 0.9 | 8.4 ± 0.9 | 8.4 ± 0.9 |
| Fasting plasma glucose (FPG)(mmol/L) | IDeg OD FF | IDeg OD | IGlar OD | Total |
|---|---|---|---|---|
| Mean | 9.0 ± 2.6 | 8.8 ± 2.8 | 9.0 ± 2.8 | 8.9 ± 2.7 |
The record gives a start of Nov 2009, a primary completion of Sep 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 5 years 2 months after primary completion. A results delay was requested in Nov 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin degludec · Insulin Glargine